关键词:

B细胞非霍奇金淋巴瘤, 沙利度胺, CHOP化疗方案, 脱发, 肝肾功能损伤, 安全性

Abstract:

Objective　To investigate the effect of thalidomide combined with CHOP chemotherapy regimen on the immune function in patients with B-cell non-Hodgkin lymphoma. Methods　From June 2018 to June 2021, a total of 86 patients with B-cell non-Hodgkin lymphoma who received first-line chemotherapy in The Second People's Hospital of Liaocheng were selected and were divided into two groups by the random number table method. In the control group, there were 21 males and 22 females, ranging in age from 16 to 55 years old, with a median age of 32.7 years old. In the combined group, there were 22 males and 21 females, ranging in age from 16 to 58 years old, with a median age of 33.6 years old. The control group received CHOP chemotherapy regimen [vincristine (1.4 mg/m² d1) + epirubicin (50 mg/m² d1) + cyclophosphamide (750 mg/m² d1) + prednisone (100 mg qd d1-5)], and the combined group was given thalidomide (100 mg/d) on the basis of CHOP chemotherapy regimen, 21 days as 1 treatment cycle. The short-term curative effects, immune function [CD₃⁺ and immunoglobulin G (IgG)], and incidences of adverse reactions of the two groups were compared. t test and χ² test were used for statistical analysis. Results　In the control group, there were 13 cases of complete response, 8 cases of partial response, and 22 cases of no response; in the combined group, there were 22 cases of complete response, 8 cases of partial response, and 13 cases of no response. The effective rate of the combined group was 69.77% (30/43), which was higher than that of the control group [48.44% (21/43)] (χ²=4.900, P=0.027). There were no statistically significant differences in the levels of CD₃⁺ and IgG between the two groups before treatment (t=0.240 and 0.146, P=0.811 and 0.884). After treatment, the levels of CD₃⁺ and IgG in the two groups were higher than those before treatment (all P<0.05), and the levels of CD₃⁺ and IgG in the combined group were higher than those in the control group (t=2.131 and 11.939, P=0.036 and <0.001). The total incidence of adverse reactions was 18.60% (8/43) in the combined group and 16.28% (7/43) in the control group, with no statistically significant difference (χ²=0.081, P=0.776). Conclusion　Thalidomide combined with CHOP chemotherapy regimen can improve the clinical efficacy and immune function in patients with B-cell non-Hodgkin lymphoma, and it is safe and worthy of promotion.

Key words:

B-cell non-Hodgkin lymphoma, Thalidomide, CHOP chemotherapy regimen, Hair loss, Liver and kidney function injury, Security